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Introduction
Acute kidney injury (AKI) is a term frequently used in 
clinical practice and kidney research; however, its mean-
ing is not always clear. The current clinical classification 
defines AKI based on functional parameters such as 
urinary output and serum creatinine (SCr) and not on 
injury markers [1,2]. This definition of AKI does not cover 
important unilateral kidney injuries such as renal colic 
or unilateral renal embolism but instead defines tran-
sient renal hypoperfusion-related decline of glomerular 
filtration rate (GFR) as AKI despite the absence of neph-
ron injury [3]. Because acute tubular necrosis (ATN) has 
been investigated in most studies addressing the role of 
the immune system in AKI, for scientific accuracy and 
to avoid further confusion, we reviewed the role of the 
immune system in ATN, whether unilateral or bilateral, 
and whether or not this results in reduced urinary output 
or increased SCr. We believe that all long-term sequelae 
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arising from an ATN episode are associated with the ir-
reversible loss of nephrons; thus, we are interested in the 
immune mechanisms that contribute to nephron loss in 
each of the ATN phases. First, we provide a short descrip-
tion of the role of the immune system in the healthy kid-
ney during homeostasis before covering recent insights 
into the role of the immune system in the early and late 
injury phases of ATN. Then, we discuss the contribution 
of the immune system to the recovery and post-recovery 
phases of ATN. Finally, we discuss the obstacles to over-
come before experimental knowledge is implemented 
into clinical practice.
The immune system of the healthy kidney during 
homeostasis 
The healthy kidney harbors numerous immune cells in 
different compartments (Fig. 1). 
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Figure 1. The immune system during 
homeostasis and necroinflammation. 
(A) Renal resident mononuclear phago-
cytes originate from the yolk sac during 
nephrogenesis. (B, C) These cells or the 
bone marrow scatter around the tubular 
basement membrane throughout the en-
tire nephron. (B) Infiltrating mononuclear 
phagocytes originate from the bone 
marrow and follow chemokine tracks to 
the injured kidney. During necroinflam-
mation (D), both resident and infiltrating 
immune cells react to danger-associated 
molecular patterns (DAMPs) released by 
dying tubular cells. By releasing more 
alarmins and DAMPs, further immuno-
genic cell death is induced, and more im-
mune cells are attracted from the bone 
marrow via the circulation.
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Resident intrarenal immune cells 
Resident immune cells in the kidney belong to the 
myeloid lineage and originate from RUNX1, KIT+, and 
CSFR+ yolk sac precursors that express the surface mark-
ers CX3CR1, F4/80hi, and CD11blow (Fig. 1A) [4,5]. The 
cells reside in large numbers within the interstitial com-
partment in close proximity to the tubular basement 
membrane, the peritubular capillaries, and interstitial 
fibroblasts (Fig. 1B, C) [6]. Cells of the same origin ap-
pear as macrophages in many organs such as the liver or 
adipose tissue, but inside the kidney, they extend longer 
dendrites into the narrow spaces between the tubules 
and have therefore been referred to as intrarenal dendrit-
ic cells [7]. Because of the plasticity between functional 
properties typical for macrophages versus dendritic cells, 
these yolk sac-derived resident renal immune cells have 
also been termed mononuclear phagocytes [8].
The role of these cells during kidney homeostasis has 
not been rigorously explored. Assumedly, they continu-
ously receive signals from the self, which maintains their 
inactive state and secretion of homeostatic signals such 
as anti-inflammatory lipid mediators and cytokines. Evi-
dence is lacking regarding the hypothesis that these cells 
clear any bacterial products, an important function of 
cells in the liver (e.g., Kupffer cells), and the nephron’s 
ultrafiltrate is usually sterile [4]. Resident mononuclear 
phagocytes contribute to the turnover of extracellular 
matrix by releasing matrix metalloproteases and remov-
ing debris from apoptotic cells (Fig. 2A) [9-11]. The latter 
is an important homeostatic function, as the rapid clear-
ance of cell debris from the extracellular space prevents 
neo-epitopes from generating secondary modifications 
that could promote autoimmunity. In fact, people with 
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Figure 2. Acute kidney injury and renal inflammation. A general misconception is that the current classification of acute kidney injury (AKI) 
is not based on markers of tubular necrosis but on markers of renal function. In fact, not the clinical representation of declined renal func-
tion, but only severity assessment of the underlying mechanisms of ATN serves as a reliable predictor of AKI-to-chronic kidney disease (CKD) 
progression. This becomes even more evident for unilateral forms of kidney injury, because serum creatinine (SCr) and urinary output usu-
ally remain unaffected in patients with normal baseline glomerular filtration rate (GFR). Nevertheless, some forms of unilateral acute kidney 
disease involve true kidney injury, renal inflammation, and necrosis such as unilateral renal embolism and thereby cover all phases of renal 
injury and regeneration. The concept of distinct phases of ATN is an extension of ideas by Sutton et al [10] and Okusa and Chertow [11]. The 
drop and recovery of GFR and the increase in SCr level are shown along the course of an AKI episode. The suggested course of AKI assumes 
that the trigger for injury was transient and not repetitive or persistent, either unilateral or bilateral. The immunological characterization of 
each underlying phase of acute tubular necrosis (ATN; A-E) is described in detail in the text.
KDIGO, Kidney Disease Improving Global Outcomes.
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genetic defects in phagocytic clearance mechanisms are 
prone to autoimmunity (e.g., systemic lupus erythemato-
sus) [12].
Circulatory blood compartment 
Immune cells such as neutrophils, granulocytes, mono-
cytes, and lymphocytes are also present inside the cir-
culatory blood compartment of the kidney. These cells 
originate from myeloid and lymphoid precursors residing 
in the bone marrow, a lineage different from that giving 
rise to the resident immune cells of the kidney (Fig. 1B, 
C, and 2A) [5]. Circulating immune cells are immature ef-
fector cells of the innate and adaptive immune systems. 
They are equipped with integrins and chemokine recep-
tors on their cell surface that allow them to be recruited 
to the kidney if kidney injury induces local expression of 
adhesion molecules and chemokines [5]. 
The immune system in the early injury phase of ATN 
Regulated necrosis 
ATN involves 2 types of necrosis, unregulated and regu-
lated. For many years, necrosis was considered merely 
an accidental, passive, and uncontrollable form of cell 
death. However, the discovery of signaling pathways of 
regulated necrosis facilitated the recognition of regulated 
necrosis and implies a therapeutic potential in ATN. Sev-
eral forms of regulated necrosis with specific signaling 
pathways have been discovered: Necroptosis (receptor-
interacting protein kinase [RIPK] 1-RIPK3-mixed lineage 
kinase domain-like [MLKL]-related [13]), ferroptosis 
(glutathione peroxidase 4-related [14]), regulated ne-
crosis mediated by mitochondrial permeability transi-
tion (MPT-RN, cyclophilin D-related [15]), pyroptosis 
(caspase-1/-11-related [16]), parthanatos (poly [adenos-
ine diphosphate-ribose] polymerase-1-related [17]), and 
NETosis (RIPK3-MLKL-related [18]). Necroptosis, ferrop-
tosis, MPT-RN, and parthanatos have been reported to 
contribute to experimental ATN. Meanwhile, pyroptosis 
and NETosis evolve as cell type-specific forms of regulat-
ed necrosis. Necroptosis contributes to ischemia reper-
fusion injury (IRI)- [19], cisplatin- [20], contrast media- 
[21], rhabdomyolysis- [22], and crystal-induced ATN [23]. 
Ferroptosis contributes to IRI-, oxalate-, and folic acid-
induced ATN [24]. MPT-RN contributes to IRI-induced 
ATN and possibly cisplatin-induced ATN [19]. Parthana-
tos contributes to IRI- and cisplatin-induced ATN [25,26]. 
Pyroptosis occurs mainly in macrophages and dendritic 
cells [27,28]. The occurrence of pyroptosis in tubule cells 
remains unclear to date. NETosis occurs in neutrophils; 
although recently, extracellular traps generated by macro-
phages have also been reported to contribute to ATN [29].
Damage-associated molecular patterns (DAMPs) 
Innate immunity is highly conserved in all species to 
prevent spread of infection. Toll-like receptors (TLRs) 
and membrane-bound pattern recognition receptors 
(PRRs) expressed in innate immune cells control in-
fection. However, TLRs and other PRRs also recognize 
DAMPs or alarmins released from damaged tubule cells 
[30]. The molecular nature of necrosis-related DAMPs 
and their receptors in kidney disease has been reviewed 
elsewhere [31]. DAMPs released from dying tubule cells 
activate DAMP receptors on immune and parenchymal 
cells. Proximal tubular cells highly express scavenger 
receptors as a response to tissue injury (e.g., phospha-
tidylserine receptor kidney injury molecule-1 [KIM-1]), 
which effectively transforms them into transient ‘semi-
professional phagocytes’ [32,33]. Consequently, DAMPs 
are also released from tubular cells undergoing ferrop-
tosis and MPT-RN. DAMP recognition activates cells to 
secrete mature proinflammatory cytokines, which in turn 
induces further necrosis. This vicious cycle is termed 
necroinflammation and is a hallmark of the early injury 
phase (Fig. 1D) [34,35]. Necroptosis is induced by tumor 
necrosis factor (TNF)-α and interferon-γ [36]. Neutro-
phil extracellular trap (NET) formation can be induced 
by TNF-α and interleukin (IL)-18 [37]. Several DAMPs 
activate NOD-like receptor protein 3 (NLRP3), resulting 
in formation of a caspase-1-activating complex, the in-
flammasome [38]. The activated inflammasome in mac-
rophages or dendric cells releases the mature proinflam-
matory cytokines IL-18 and IL-1β; the inflammasome 
can also be activated by kidney-specific DAMPs such as 
uromodulin [39]. IL-1 activates IL-1R/MyD88 signaling, 
which activates NF-κB-dependent transcription of proin-
flammatory cytokines and chemokines, a process under 
control of p53/MDM2 [40]. DAMP-induced NLRP3 acti-
vation may also trigger pyroptosis [16]. Certain DAMPs 
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directly promote NET formation. For example, expelled 
histone, a main component of extracellular chromatin, 
directly damages renal tubule cells and induces TLR/
NLRP3-related inflammation [41,42]. DAMPs can also ac-
tivate dendric cells [43].
Neutrophil-driven sterile inflammation 
During ATN, neutrophils and natural killer T (NKT) 
cells first emerge at injured sites (Fig. 2B) [44]. Whether 
NKT cells directly damage tubule cells remains under 
debate [45]. In contrast, neutrophils play a central role 
in driving sterile inflammation. After IRI, neutrophils 
appear in the peritubular capillaries as early as 30 min-
utes. Neutrophils adhere to the vascular endothelium by 
binding to intercellular adhesion molecule-1, E-selectin, 
L-selectin, and integrin [46] and migrate into the intersti-
tium, where further tubular injury is promoted by release 
of proinflammatory cytokines/chemokines and reactive 
oxygen species [47]. Neutrophils also release DAMPs, 
such as histones, and form NETs. NETs and NET-derived 
DAMPs mediate renal necroinflammation and induce re-
mote organ injury (Fig. 1D and 2B) [41].
The immune system in the late injury phase of ATN 
In the late injury phase of ATN, different immune cells 
such as infiltrating bone marrow monocyte-derived M1 
macrophages enter the process (Fig. 2C) [48]. Damaged 
tubular cells as well as resident mononuclear phago-
cytes attract circulatory immune cells such as CCR2+ 
monocytes by releasing DAMPs and chemokines [49]. 
Due to the proinflammatory microenvironment, these 
cells develop a M1 phenotype, which has been shown to 
contribute to kidney damage in the late injury phases of 
ATN [50,51]. Accordingly, depletion or reduction of M1 
macrophages within the first 48 hours after renal injury is 
associated with less functional and structural damage in 
experimental models of ATN [46,52]. The proinflammato-
ry environment in the damaged area is augmented by the 
ongoing auto-amplification loop of necroinflammation. 
Parenchymal cells undergoing necroptosis, ferroptosis, 
parthanatos, or MPT-RN continue to release DAMPs such 
as adenosine triphosphate (ATP), histones, heat shock 
proteins, and alarmins, which have both direct cytotoxic 
effects and immunostimulatory effects via PRRs. DAMPs 
and alarmins further drive regulated cell death. This can 
be a synchronized process, breaking down whole func-
tional units of an organ (e.g., nephrons) and finally lead-
ing to organ failure or even sepsis and death [53]. Howev-
er, when and how this auto-amplification loop terminates 
remain unanswered. The long-term outcome of ATN 
depends at least partially on the predominant macro-
phage phenotype present at the site of inflammation [49]. 
The macrophage capacity to undergo phenotype shifts 
appears to influence all subsequent phases of ATN by af-
fecting the intrarenal microenvironment [54]. During the 
injury phase, DAMPs, interferon-γ, and TNF, produced 
by NK-cells and CD4+ TH1 and CD8+ T cells, prime the 
incoming M0 monocytes toward the proinflammatory 
M1 macrophage phenotype that contributes to the ongo-
ing necroinflammation and kidney injury [50,55]. Over 
the course of events, the macrophage phenotype changes 
toward an anti-inflammatory effector function. It is not 
fully understood how this conversion occurs on the mo-
lecular level. Most of the knowledge is gained through 
in-vitro experiments and cannot be used to adequately 
explain the correlations within the much more complex 
and permanently adapting microenvironments in vivo. 
The M1-M2 shift is a complex interaction of outside-in 
signalling of different cytokines with the help of specific 
T-helper and regulatory T cells and delayed negative 
signaling of TLR within the macrophage [56]. During the 
process of wound healing, the clearing of neutrophils 
that underwent NET formation has been suggested to 
likely be associated with the shift in macrophage polar-
ization (Fig. 2D) [57]. Adenosine promotes the shift to 
anti-inflammatory and angiogenic M2 macrophages by 
binding A2 receptors [58]. In addition, colony stimulating 
factor-1 (CSF-1) secreted by renal tubular cells enhances 
the expansion of M2 macrophages [59].
The alternatively activated M2 macrophages establish a 
predominantly anti-inflammatory micromilieu secreting 
IL-1R2, IL-10, and transforming growth factor-β (TGF-β) 
among others. Notably, the detailed characterization of 
in vitro classically activated M1 and alternatively acti-
vated M2 macrophages represent only the extremes of a 
potentially more mixed population of transient activation 
states in vivo [60]. The changing microenvironment and 
the macrophage phenotype switch mark the transition 
from injury to the recovery phase; epithelial and tubular 
repair mechanisms, proliferation, and fibrosis begin to 
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predominate [61]. Without this change toward an anti-
inflammatory micromilieu, necroinflammation leads to 
cell death and tissue damage [62]. 
The immune system in the recovery phase of ATN 
Role of DAMPs and TLRs 
Blocking TLRs in the context of ATN shows a mixed 
phenomenon; in the early injury phase, blocking TLRs 
prevents necroinflammation, whereas late blocking 
impairs recovery and renal outcome [63]. DAMPs, such 
as ATP, histone, and high mobility group box 1 protein, 
are strong proinflammatory triggers in sterile necroin-
flammation by activating TLRs, thereby initiating the 
expression and release of cytokines and chemokines in 
phagocytes [64-68]. However, DAMP-mediated TLR sig-
naling also leads to the secretion of immunoregulatory 
mediators such as IL-22, a cytokine with pro-proliferative 
and pro-regenerative properties [69-71]. Phagocytes 
secrete IL-22, especially during inflammation [72]. IL-
22 signaling is important for maintaining the integrity 
of the epithelial barrier and its recovery after injury in 
many different organs. Therefore, as expected, IL-22 re-
ceptors are mostly expressed on epithelial cells [73]. IL-
22 signaling supports cell proliferation via the PI3K/Akt/
mTOR pathway [74] and upregulation of cyclin D1 and 
CDKN4 [71]. Conversely, IL-22 enhances cell survival by 
downregulating pro-apoptotic factors including Bax and 
Bad and upregulating anti-apoptotic factors such as Bcl-
2 via induction of STAT3 and ERK1/2 phosphorylation 
[69]. TLR signaling shows that activation of one biological 
mechanism, in this case necroinflammation, is closely 
associated with its counterregulatory mechanisms.
Resolution of inflammation 
The fundamental condition that allows regeneration 
in any organ is resolution of the inflammatory milieu 
[75]. This is necessary for regeneration of the epithe-
lium and restoration of a new host defense barrier [62]. 
The importance of this process can be seen in chronic 
dermal ulcers, which do not heal unless the inflamma-
tory signal disappears, when comparing recovery after 
necroinflammation with dermal wound healing after 
injury. Resolution of the inflammatory milieu indicates 
the final eradication of pathogens and sterile wound 
conditions. Mononuclear phagocytes play an important 
role in changing the inflammatory milieu in the kidney. 
After phagocytosis of necrotic cell debris, these cells initi-
ate the regenerative process of the nephron by removing 
apoptotic cells (Fig. 2D). Apoptosis, in contrast to necrot-
ic forms of cell death, is a balanced physiological mecha-
nism, which is not immunogenic but enhances epithelial 
healing [76,77]. Hence, apoptosis of immune cells, such 
as neutrophils and T-cells, represents a regulated physi-
ological mechanism that limits an inappropriate immune 
response. Humoral factors such as C1q, mannose-binding 
lectin, and pentraxins support this process by opsonizing 
apoptotic cell debris [78-80]. The phagocytosis-related 
clearance of apoptotic cells further drives the polarization 
of mononuclear phagocytes from an M1- to an M2-like 
phenotype that favors changes in the inflammatory mi-
lieu toward anti-inflammatory conditions by secreting IL-
10 and TGF-β [81,82]. Phagocytosis of dead cells and the 
release of an anti-inflammatory cytokine-cocktail enables 
immune cells, especially phagocytes, to dissolve the in-
flammatory signal in the nephron and allow epithelial and 
vascular healing. M2 macrophages also directly support 
parenchymal healing by secreting growth factors such as 
TGF-β, hepatocyte growth factor, epidermal growth factor, 
vascular endothelial growth factor-C, and platelet-derived 
growth factor [75]. These trophic functions of alterna-
tively activated macrophages that also greatly contribute 
to embryonic nephrogenesis by increasing overall kidney 
growth and ureteric bud branching [83] can be addition-
ally triggered in postnatal kidney repair. CSF-1 treatment 
rapidly accelerated renal repair after ischemic injury in 
vivo by altering the intrarenal macrophage population 
[84]. These results emphasize the crucial contribution of 
immune cells not only to collateral tissue damage, but 
also to solid organ regeneration.
Cell cycle activation in differentiated tubular cells versus 
progenitor cells 
As an immediate response to tubular cell loss during 
ATN, the surviving differentiated tubular cells rapidly 
undergo aberrant cell cycles (endoreplication cycles or 
endocycles) to increase size and function, presenting as 
cell hypertrophy (Fig. 2D) [85]. True regeneration, i.e., 
division of surviving cells to replace lost tubular cells by 
Kundert, et al. Immune mechanisms in AKI
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daughter cells as a result of a completed G2/M phase of 
the cell cycle (mitosis) occurs rarely and is limited to scat-
tered intrarenal progenitor cells residing mostly in the S3 
segment of the proximal tubule and the thick ascending 
limb of the loop of Henle (Fig. 2D) [85,86]. Clonal prolif-
eration of surviving progenitors in each single nephron 
determines the regenerative capacity of the kidney after 
ATN as humans and mammals cannot produce nephrons 
de novo; approximately only 50% of the irreversibly lost 
tubular cells during the injury phase are replaced by regen-
eration [85]. When differentiated tubular cells are forced to 
enter the cell cycle during the DNA damage and uncom-
pleted DNA repair phase, this may lead to mitotic catastro-
phe, detachment, and further tubular cell losses beyond 
the initial injury and collateral damage caused by sterile in-
flammation. Currently, this mode of cell loss after injury is 
well described for podocytes [87-90], and although direct 
proof of mitotic catastrophe in renal tubular cells is lacking, 
evidence indicates that inhibition of cell cycle progression 
can be beneficial in models of ATN [91-94]. 
Mesenchymal healing 
Mesenchymal healing is required to mechanically stabi-
lize the remnant nephrons during the regeneration phase 
and fill the gaps of irreversibly lost nephrons. Thus, dur-
ing the regeneration phase, fibrotic and vascular growth 
factors are simultaneously released with epithelial growth 
factors, a response that may be transient until epithelial 
healing is completed [95]. Insufficient epithelial healing 
leads to a persistent release of mesenchymal growth fac-
tors that induce a second line of defense, mesenchymal 
healing (Fig. 2E) [96]. Eventually, this also can lead to 
fibrosis with impaired renal function because interstitial 
fibrosis promotes vascular rarefication, tubular isch-
emia, and tubular atrophy [97-99]. Non-inflammatory 
M2 macrophages and bone marrow-derived fibrocytes 
promote the formation of fibrosis by releasing TGF-β 
and collagen matrix. Cell cycle arrest of epithelial cells in 
the G2/M phase leads to persistent TGF-β secretion and 
interstitial fibrogenesis [100], but this interpretation was 
based on the assumption that cell cycle marker p-histone 
H3 only indicates the G2/M phase. However, new data in-
dicate that polyploid tubular cells undergoing endocycles 
and resting in the G1 cells also express p-histone H3. The 
tubular cells secrete TGF-β along with numerous other 
proteins and mediators as a sign of the hypersecretory 
state of compensatory cell hypertrophy [85]. This mecha-
nism may explain why ATN can be followed by CKD as 
a result of pathomechanisms that ensure survival in the 
acute phase but evolve into maladaptive repair over time.
The intrarenal immune system in the post-
recovery phase of ATN 
The outcome after ATN is influenced by the number of 
lost nephrons during the injury phase and reconstitution 
of the remnant nephrons during the repair phase. When 
tubular regeneration fails, patients develop CKD with 
impaired renal function and structural changes in the 
kidney such as tubular atrophy and interstitial fibrosis 
(Fig. 2E) [101]. Reduced renal function causes alterations 
in immunity, observed both in persistent systemic ster-
ile inflammation and in acquired immunosuppression 
[102]. Accordingly, patients suffering from CKD fail to 
generate an appropriate immune response to infections 
[103], a condition that can be largely explained by uremic 
toxin-induced immune suppression. Uremia triggers 
neutrophil apoptosis and oxidative burst in mononuclear 
phagocytes [104]. Furthermore, patients with CKD have 
higher blood level of the plasma protein fibroblast growth 
factor 23, which is associated with impaired neutrophil 
recruitment during infection [105]. These two factors, 
persistent systemic inflammation and immunosuppres-
sion, contribute to the mortality of CKD patients. 
Obstacles to overcome before translating 
experimental findings into clinical practice 
Late diagnosis 
The definition of AKI currently does not rely on early 
injury markers but on kidney excretory dysfunction mark-
ers that increase only in the late injury phase [2]. However, 
drugs interfering with the inflammatory phase of ATN 
should have already been administered during the early 
injury phase. Implementing routine screening using kid-
ney injury markers (e.g., tissue inhibitor of metalloprotein-
ases 2 and insulin-like growth factor binding protein-7) 
in high-risk patients to identify ATN within a window of 
opportunity represents the most promising option for ef-
fective targeting of necroinflammation [106,107].
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Animal models 
Although cisplatin nephropathy is similar in rodents 
and humans, other forms of human ATN encompass a 
complex pathophysiology difficult to mimic in rodent 
models [108-110]. For example, renal pedicle clamping 
is frequently used in rodents but is an infrequent cause 
of ATN in humans. In addition, also other rodent study 
settings do not match the clinical setting [111]. Young, 
inbred rodents of the same sex do not mimic the geneti-
cally heterogenous, gender-mixed elderly population 
frequently affected by ATN. In addition, rodents cannot 
be dialyzed to survive severe AKI like humans. Hence, 
sublethal AKI episodes in rodents hardly mimic clinically 
relevant severe ATN episodes. 
Human AKI often represents underlying CKD 
In epidemiological studies, AKI was reported as a dis-
ease of the elderly [112], possibly an artifact due to the 
SCr criterion of the current AKI definition. Injury to 
50% of nephrons will not increase SCr level in patients 
with a normal baseline GFR, while minor nephron inju-
ries would increase SCr level in patients with impaired 
baseline GFR. Therefore, the clinical diagnosis of AKI is 
largely confounded by underlying CKD, which is ignored 
by animal experimentation, clinical trial design, and tar-
get selection. In addition, ‘CKD upon AKI,’ which finally 
includes the concept of AKI-related nephron loss, largely 
depends on baseline GFR, underlying CKD, and age [101].
Nephron number 
The current functional definition of AKI integrates too 
many variables especially renal reserve as well as excess 
nephrons and hypertrophy. Demonstrating the effects 
of anti-inflammatory drugs would require preventing 
immunopathology-related nephron loss; however, no 
biomarker for nephron number is available at present 
[107]. In addition, the best time point for evaluation of 
AKI-related nephron loss after AKI is unclear.
Summary
The immune system is involved in all phases of ATN. 
During homeostasis, resident yolk sac-derived mono-
nuclear phagocytes contribute to immune tolerance and 
turnover of interstitial matrix. Upon injury, these cells 
employ TLRs, inflammasomes, and other PRRs to trans-
late the presence of DAMPs released from necrotic pa-
renchymal cells into a release of extracellular cytokines 
and chemokines. Neutrophils are the first blood-derived 
immune cells to enter the site of injury and often un-
dergo NET formation, a process setting off the crescendo 
of renal necroinflammation. In the late injury phase, 
the recruitment of CCR2+ M1 macrophages further en-
hances necroinflammation and renal dysfunction. In the 
recovery phase, M2-macrophages and the CSF-1-driven 
proliferation of resident myeloid cells counteract the in-
flammatory process by phagocytic clearance of dead pa-
renchymal cells and NET-related chromatin and proteins. 
These cells secrete numerous immunoregulatory media-
tors that promote the resolution of necroinflammation 
unless repetitive episodes or persistent kidney injury pro-
long the injury phase. Healing processes include re-ep-
ithelialization, angiogenesis, and a transient fibrotic re-
sponse. Over time, resident and infiltrating immune cells 
can reconstitute homeostasis once nephron regeneration 
is completed. Defect healing upon irreversible nephron 
loss implies persistent scar formation to which these cells 
also contribute by secreting collagen I and profibrotic 
mediators. Hence, the ultimate outcome after an ATN 
episode depends on the extent of irreversible nephron 
loss during the injury phase. The capacity of remnant 
nephrons to undergo compensatory hypertrophy sup-
ports functional recovery of renal function. Conversely, 
GFR recovery frequently leads to underestimation of true 
nephron loss during an ATN episode.
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